VISUAL OUTCOMES AND INCIDENCE OF RECURRENT VITREOUS HEMORRHAGE AFTER VITRECTOMY IN DIABETIC EYES PRETREATED WITH BEVACIZUMAB (AVASTIN)

• DOI: 10.1097/iae.0b013e3181a8eb88
• Publication Date: 2009-07-02T07:19:09Z
• Authors: WAYNE R. LO; STEPHEN J. KIM; THOMAS M. AABERG; CHRISTOPHER BERGS...; SUNIL K. SRIVASTAVA; JIONG YAN; DANIEL F. MARTIN; G BAKER HUBBARD
• Keywords: Vitreous hemorrhage

In Brief Purpose: To evaluate the safety and effect of bevacizumab pretreatment on incidence recurrent vitreous hemorrhage visual acuity after vitrectomy for proliferative diabetic retinopathy. Methods: This was a consecutive, retrospective, comparative cohort study. Patients undergoing from September 2006 through November 2007 at Emory Eye Center complications retinopathy were identified reviewed. A total 33 eyes pretreated with 104 untreated observed postoperative final acuity. Results: in group significantly younger than those (average age, 46.4 vs. 58.4 years) more likely to have 20-gauge instrumentation (58% 36%). An average 9.6 days passed between injection surgery. Early (4-6 weeks) rebleed rates 15% versus 13% groups, respectively, not statistically different. Preoperative (7/200 count finger 4′), 1-month (20/200−3 20/150), 3-month (20/100−3 20/100+2) different groups. No statistical difference found regarding gauge vitrectomy. Conclusion: Bevacizumab associated any but did influence or this retrospective series. The overall early series seems lower historically reported rates. study performed patients seem affect complications. 13%.